Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

LYSOZYME, a bacteriolytic enzyme discovered in 1922 by Sir Alexander Fleming, 2 is found in a number of biologic fluids. The enzyme is a basic protein of low molecular weight that lyses ...

Endovascular treatment (EVT) of stroke with large-vessel occlusion is known to be safe and effective. The effect of EVT for occlusion of medium or distal vessels is unclear. We randomly assigned ...

Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear. In a multicenter, prospective ...

Familial HLH is a success story in modern medicine. Initially a disease that was largely unknown and fatal, it is now understood on a molecular level and is curable. Moreover, HLH is an archetype ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...

A total of 867 patients underwent randomization: 291 were assigned to receive acalabrutinib–venetoclax, 286 acalabrutinib–venetoclax–obinutuzumab, and 290 chemoimmunotherapy (of whom 143 ...

In this Journal feature, information about a real patient is presented in stages (boldface type) to an expert clinician, who responds to the information by sharing relevant background and ...